5 results
The primary objective of this study is to obtain clinical proof of principle that the addition of a PgP/BCRP inhibitor increases CNS concentrations of tyrosine kinase inhibitors by inhibition of drug efflux transporter function in the blood brain…
1. What are the effects of cinacalcet on clinical and biochemical parameters, including bone turnover markers, in patients with primary hyperparathyroidism due to a MEN-I mutation?2. What are the effects of cinacalcet on bone mineral density and…
To determine the pharmacokinetic properties of a new elacridar formulation
Secondary HPT is common in people with CKD. Patients with secondary HPT often have high PTH levels and may develop large parathyroid glands in the neck. Patients with secondary HPT may have bone disease (osteodystrophy). This bone disease may cause…
The aim of the RHINO trial is to compare the effect of parathyroidectomy and cinacalcet treatment on quality of life in end-stage renal disease patients with hyperparathyroidism and to evaluate cost-effectiveness. The aim of this pilot study is to…